Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy
- 15 July 1990
Abstract
Ninety‐one patients with invasive breast carcinoma with a diameter of 1 cm or less and histologically negative axillary nodes were treated between 1976 and 1986 with radical surgery alone (67), or with conservative surgery (24). Cases were analyzed in relation to tumor size, steroid receptors, histologic and nuclear grade, age, and type of therapy, none of which showed a significant relationship to relapse or survival. There were 22% well‐differentiated, 20% moderately differentiated, and 56% poorly differentiated or anaplastic tumors. Estimated disease‐free survival (DFS) for this group was 91% at 7 years, and overall survival 96% for the same period. There were five relapses (all among poorly differentiated tumors) and three deaths unrelated to breast cancer. With the three deaths censored, 100% of the well‐differentiated and moderately differentiated tumors were disease‐free at 7 years versus 91% for poorly differentiated and anaplastic tumors (P = 0.076). These data suggest that node‐negative patients with minimal invasive breast cancer are highly curable by primary surgical therapy alone, and the authors believe that these patients are not appropriate candidates for adjuvant therapy until such time as subgroups at high risk of recurrence can be identified.This publication has 40 references indexed in Scilit:
- Breast Cancer Therapy: Exercising All Our OptionsNew England Journal of Medicine, 1989
- Adjuvant Therapy of Node-Negative Breast CancerNew England Journal of Medicine, 1989
- Adjuvant Treatment of Early Breast CancerNew England Journal of Medicine, 1989
- Prolonged Disease-Free Survival after One Course of Perioperative Adjuvant Chemotherapy for Node-Negative Breast CancerNew England Journal of Medicine, 1989
- Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast CancerNew England Journal of Medicine, 1989
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- A Randomized Clinical Trial Evaluating Sequential Methotrexate and Fluorouracil in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor-Negative TumorsNew England Journal of Medicine, 1989
- Meeting Highlights: Adjuvant Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1988
- Oestrogen receptors in primary breast cancerBritish Journal of Cancer, 1985
- Histological Grading and Prognosis in Breast CancerBritish Journal of Cancer, 1957